Penicillium chrysogenum: Beyond the penicillin

Barreiro, Carlos; Albillos, Silvia M.; García-Estrada, Carlos

doi:10.1016/bs.aambs.2024.02.006

Advances in Applied Microbiology

2024

DOI: 10.1016/bs.aambs.2024.02.006

|View full text |Cite

Penicillium chrysogenum: Beyond the penicillin

Carlos Barreiro,

Silvia M. Albillos,

Carlos García-Estrada

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 292 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The Immunosuppressant Tacrolimus (FK506) Facing the 21st Century: Past Findings, Present Applications and Future Trends

Barreiro,

Ibañez,

Garrido-Chamorro

et al. 2024

Fermentation

View full text Add to dashboard Cite

The confluence of a large variety of factors, achievements and developments has resulted in the current long-term success in graft transplants. Some of these events are reviewed, paying special attention to immunosuppressant drugs, which are one of the most relevant milestones in the prevention of organ transplant rejection. The discovery, industrial exploitation, mechanisms of action and side effects of several drugs exhibiting immunosuppressive effects (e.g., corticosteroids, nitrogen mustards, mycophenolic acid, rapamycin) are deeply detailed. Furthermore, new trends in immunosuppressant research, improvement and reformulation are also reviewed. Nevertheless, the core of the manuscript is the immunosuppressant tacrolimus, also called FK506, which has been sought after due to the commercial success of cyclosporine and other immunosuppressant compounds, but also because of the side effects of those previous compounds. Thus, in the mid-1980s tacrolimus was described as a more potent immunosuppressive molecule, with less undesirable effects. Currently, tacrolimus is a well-stablished API that is used as a clinical treatment to avoid graft rejection, but also shows interesting properties in terms of decreasing the impact of some autoimmune diseases and acting as an enhancer of nerve regeneration treatments. Thus, in the 40th anniversary of its discovery, this paper describes the current state of the art of this drug and how it is adapting to new social needs and clinical trends.

show abstract

The Immunosuppressant Tacrolimus (FK506) Facing the 21st Century: Past Findings, Present Applications and Future Trends

Barreiro,

Ibañez,

Garrido-Chamorro

et al. 2024

Fermentation

View full text Add to dashboard Cite

show abstract

Progress in the Study of Natural Antimicrobial Active Substances in Pseudomonas aeruginosa

Si,

Wang,

Yan

et al. 2024

Molecules

View full text Add to dashboard Cite

The prevalence of antimicrobial resistance reduces the effectiveness of antimicrobial drugs in the prevention and treatment of infectious diseases caused by pathogens such as bacteria, fungi, and viruses. Microbial secondary metabolites have been recognized as important sources for new drug discovery and development, yielding a wide range of structurally novel and functionally diverse antimicrobial drugs for the treatment of a variety of diseases that are considered good producers of novel antimicrobial drugs. Bacteria produce a wide variety of antimicrobial compounds, and thus, antibiotics derived from natural products still dominate over purely synthetic antibiotics among the antimicrobial drugs developed and introduced over the last four decades. Among them, Pseudomonas aeruginosa secondary metabolites constitute a richly diverse source of antimicrobial substances with good antimicrobial activity. Therefore, they are regarded as an outstanding resource for finding novel bioactive compounds. The exploration of antimicrobial compounds among Pseudomonas aeruginosa metabolites plays an important role in drug development and biomedical research. Reports on the secondary metabolites of Pseudomonas aeruginosa, many of which are of pharmacological importance, hold great promise for the development of effective antimicrobial drugs against microbial infections by drug-resistant pathogens. In this review, we attempt to summarize published articles from the last twenty-five years (2000–2024) on antimicrobial secondary metabolites from Pseudomonas aeruginosa.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Penicillium chrysogenum: Beyond the penicillin

Cited by 2 publications

References 292 publications

The Immunosuppressant Tacrolimus (FK506) Facing the 21st Century: Past Findings, Present Applications and Future Trends

The Immunosuppressant Tacrolimus (FK506) Facing the 21st Century: Past Findings, Present Applications and Future Trends

Progress in the Study of Natural Antimicrobial Active Substances in Pseudomonas aeruginosa

Contact Info

Product

Resources

About